U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients

The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.

from Health and Science https://ift.tt/bkIv6Of
https://ift.tt/PGF1R6K
https://ift.tt/60Ruvdw